Clozapine vs Ziprasidone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Clozapine

Marketed by HLS Therapeutics Inc.

Approved in Schizophreniasmall molecule
Weak signal

NCT00250575 · Phase 3 · completed

The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.

Next expected readout: April 2027 · NCT04580134 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)

Result source: NCT03510325

Ziprasidone

Marketed by Viatris and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00159770 · Phase 3 · completed

This 12-week, open-label, multicentre trial randomized 293 patients with chronic schizophrenia to ziprasidone (n=147) or to a comparator group of olanzapine, risperidone or quetiapine chosen by the investigator (n=146). The primary endpoint was total PANSS score, tested for non-inferiority with a margin of 7 points to the disadvantage of ziprasidone. Ziprasidone was non-inferior to the comparator group on total PANSS and on all subscores (P<0.0001), so the primary endpoint was met. The figures come from the peer-reviewed paper (Lublin et al., World J Biol Psychiatry 2009), whose abstract does not give a confidence interval.

Next expected readout: February 2027 · NCT03781115 (registry estimate)

Reported efficacy

Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial (From Baseline up to Week 8); Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in the Barnes Akathisia Scale (BAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Participants With High and Low Levels in Serum Prolactin Concentration (Baseline, Week 8); Vital Signs: Systolic and Diastolic Blood Pressure Levels (Baseline, Week 1, Week 2, Week 4, Week 6, Week 8); Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec) (6 hours after dosing of Weeks 1, 2 and 8); Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline, Week 2, Week 4, Week 6, Week 8); Percentage of Participants With Response (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Treatment-emergent Adverse Events During Randomized Trial (From Baseline up to Week 8): Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). (missed)

Result source: NCT00403546

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClozapineZiprasidone
PANSS total, change—Not posted · NCT00649844—Not posted · NCT00159770
CGI-S, change—Not posted · NCT00649844-1.2 vs -1.2vs Haloperidolwk 0.43 · n 188NCT00723606
PANSS response—Not posted · NCT00649844—Not posted · NCT00159770
PSP, change—Not posted · NCT00649844—Not posted · NCT00159770
Relapse (% of patients)—Not posted · NCT00649844—Not posted · NCT00159770

PANSS total, change

Clozapine
—Not posted · NCT00649844
Ziprasidone
—Not posted · NCT00159770

CGI-S, change

Clozapine
—Not posted · NCT00649844
Ziprasidone
-1.2 vs -1.2vs Haloperidolwk 0.43 · n 188NCT00723606

PANSS response

Clozapine
—Not posted · NCT00649844
Ziprasidone
—Not posted · NCT00159770

PSP, change

Clozapine
—Not posted · NCT00649844
Ziprasidone
—Not posted · NCT00159770

Relapse (% of patients)

Clozapine
—Not posted · NCT00649844
Ziprasidone
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clozapine: 3 of 4 rows · Ziprasidone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClozapineZiprasidone
Dropout rate
41.7%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT00498550 · Phase 4 · registry result, not featured evidence
17.2%
NCT02404155 · Phase na · registry result, not featured evidence
—High doseb
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
—High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
26.8%
NCT00338949 · Phase 4 · registry result, not featured evidence
58.5%
NCT00406315 · Phase 4 · registry result, not featured evidence
12.5%
NCT00351000 · Phase 4 · registry result, not featured evidence
2.1%
NCT00723606 · Phase 3 · registry result, not featured evidence
99.1%
NCT00139737 · Phase 3 · registry result, not featured evidence
88.4%
NCT00174447 · Phase 3 · registry result, not featured evidence
35.7%
NCT00538642 · Phase na · registry result, not featured evidence
0%
NCT00225498 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT00498550 · Phase 4 · registry result, not featured evidence
—
NCT02404155 · Phase na · registry result, not featured evidence
—High doseb
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
—High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
—
NCT00338949 · Phase 4 · registry result, not featured evidence
16.2%
NCT00406315 · Phase 4 · registry result, not featured evidence
—
NCT00351000 · Phase 4 · registry result, not featured evidence
1.1%
NCT00723606 · Phase 3 · registry result, not featured evidence
16.9%
NCT00139737 · Phase 3 · registry result, not featured evidence
44.2%
NCT00174447 · Phase 3 · registry result, not featured evidence
—
NCT00538642 · Phase na · registry result, not featured evidence
—
NCT00225498 · Phase na · registry result, not featured evidence
Serious AEs
13%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
26.7%
NCT00498550 · Phase 4 · registry result, not featured evidence
6.9%
NCT02404155 · Phase na · registry result, not featured evidence
—High doseb
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
10.5%High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
6.7%
NCT00338949 · Phase 4 · registry result, not featured evidence
9.1%
NCT00406315 · Phase 4 · registry result, not featured evidence
0%
NCT00351000 · Phase 4 · registry result, not featured evidence
0%
NCT00723606 · Phase 3 · registry result, not featured evidence
9.7%
NCT00139737 · Phase 3 · registry result, not featured evidence
30.2%
NCT00174447 · Phase 3 · registry result, not featured evidence
0%
NCT00538642 · Phase na · registry result, not featured evidence
0%
NCT00225498 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
other-sialorrhea 43.5%
weight gain 30.4%
sedation 21.7%
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
gastrointestinal disorder - other: hypersalivation 66.7%
somnolence 60%
weight gain 40%
NCT00498550 · Phase 4 · registry result, not featured evidence
salivation 68.2%
sedation 52.9%
malaise 52.6%
NCT02404155 · Phase na · registry result, not featured evidence
High doseb
hypertension 18.4%
somnolence 15.8%
headache 10.5%
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 6 more results
insomnia 6.7%
akathisia 3.3%
NCT00338949 · Phase 4 · registry result, not featured evidence
insomnia 19.1%
somnolence 14.5%
nausea 11.6%
NCT00406315 · Phase 4 · registry result, not featured evidence
difficulty breathing 4.2%
dizziness 4.2%
NCT00351000 · Phase 4 · registry result, not featured evidence
dizziness 3.7%
somnolence 3.7%
akathisia 3.2%
NCT00723606 · Phase 3 · registry result, not featured evidence
electrocardiogram qt prolonged 13.9%
insomnia 6.3%
anxiety 4.5%
NCT00139737 · Phase 3 · registry result, not featured evidence
anxiety 23.3%
insomnia 16.3%
schizophrenia 14%
NCT00174447 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clozapine

Cannabis Use Intensity Joints Per 2.36 vs 2.35 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 10.21 weeks as posted
Cannabis Use Frequency Days Per 0.14 vs 0.15 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 4.26 days as posted
Cannabis Use Joints Per 0.02 per week
absolute value · per week
No placebo or comparator arm
NCT00498550 · Phase 4 · registry result, not featured evidence

Ziprasidone

PANSS Total -4.03 score @ 2wkHigh dose
absolute change · score
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 3 more results
-5.08 score @ 4wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
-8.73 score @ 6wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
-8.62 score @ 8wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
PANSS 24.2% (n=33) @ 2wkHigh dose
responder rate · % of participants
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 3 more results
23.1% (n=33) @ 4wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
36.4% (n=33) @ 6wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
33.3% (n=33) @ 8wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
CGI-S -0.25 score @ 8wkHigh dose
absolute change · score
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 1 more result
-0.76 score @ 16wk
NCT00406315 · Phase 4 · registry result, not featured evidence
CGI-I -0.57 score @ 8wkHigh dose
absolute value · score
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 1 more result
2.7 score @ 16wk
NCT00406315 · Phase 4 · registry result, not featured evidence
Insulin Sensitivity 0.407 vs 0.072 Control minutes @ 26wk
absolute change · minutes
NCT00338949 · Phase 4 · registry result, not featured evidence
Visceral Adipose Tissue Volume 392 vs 315 Control mm @ 26wk
absolute change · mm
NCT00338949 · Phase 4 · registry result, not featured evidence
Weight -1.09 kg @ 16wk
absolute change · kg
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
Total Cholesterol Change mg/dL -3 mg @ 16wk
absolute change · mg
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
HbA1c 0.1% (n=127) @ 16wk
absolute change · percentage points
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
Fasting Glucose Change mg/dL 0.17 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 3 mg/dL as posted
show 2 more results
0.28 mmol/L @ 6wk*
NCT00351000 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 5 mg/dL as posted
-0.25 mmol/L @ 6wk*
NCT00351000 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -4.5 mg/dL as posted
Fasting Insulin 134.8 mL @ 16wk
absolute change · mL
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Total -6.61 score @ 16wk
absolute change · score
No placebo or comparator arm
Total Score, Week 16 LOCF (n=231)
NCT00406315 · Phase 4 · registry result, not featured evidence

+ 21 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Ziprasidone's landscape